Integrity (IGAP) 2.8200 $IGAP
GlucoTrack® Maker Submitted Pre-Submission Supplement to US FDA
PR Newswire - Wed Jun 01, 8:06AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes, announced that it has set a conference call with the United States Food and Drug Administration (FDA), expected to take place in July 2016, for further discussion regarding the Company's pre-submission supplement (including clinical trial protocol) for its GlucoTrack® Model DF-F device submitted to the FDA for review on May 10, 2016. Such protocol was modified to reflect FDA remarks and discussions with the Company during a Pre-Submission meeting which took place in October 2015. Following the July discussion and subject to FDA approval of the Company's clinical trial protocol, the Company plans to initiate the pivotal clinical study in the third quarter of 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.90 (+0.23)
GlucoTrack® maker to Present at Marcum and LD Micro Investor Conferences on June 2nd in New York City and June 7th in Los Angeles
PR Newswire - Tue May 31, 8:13AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that CEO Avner Gal will present at the Marcum and LD Micro investor conferences on Thursday, June 2nd at 11:30 am EDT and Tuesday, June 7th at 11:30 am PDT, respectively.
GlucoTrack® Maker Names Two New Board Members
PR Newswire - Wed Mar 23, 8:30AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced today that it appointed Angela Strand and Leslie Seff to its Board of Directors, effective March 23, 2016. Ms. Strand will also chair the newly formed Nominating and Corporate Governance Committee of the Board.
JNJ: 119.92 (-0.80), NKTR: 17.26 (-0.46)
Blood Glucose Testing and Diabetes Management Study 2015
M2 - Tue Feb 02, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5ttq8/blood_glucose) has announced the addition of the "Blood Glucose Testing and Diabetes Management" report to their offering. The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing - or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor - has emerged as a strong force in the blood glucose testing segment. The purpose of this report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Key Topics Covered: 1. Overview 2. Diabetes 2.1 Demographics of Diabetes 2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes 2.3 Economics of Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 3.1 Worldwide Glucose Testing Market 3.2 U.S. Market 3.3 European Market 3.4 Asian Market 3.5 Competitive Situation 3.6 Market Drivers and Restraints 3.7 Market and Product Trends 3.8 Strategic Recommendations 3.9 Competitive Strategies 3.10 New Opportunities in the Professional Blood Glucose Meter Market 3.11 Adjacent Markets 4. Glucose Diagnostic and Monitoring Recommendations 4.1 Diagnosis of Diabetes Mellitus 4.2 Tight Glucose Control in Treating Diabetes 4.3 Recommendations for Glucose Control in Diabetic Patients 4.4 Hypoglycemia and Treatment 5. Glucose Testing Technology Platforms and Consumable Products 5.1 Types of Glucose Determination Technologies 5.2 Enzymatic Reactions Used to Determine Glucose Concentrations 5.3 Development of Blood Glucose Monitors: A Historical Evaluation 5.4 Accuracy and Precision in Glucose Meters 5.5 Key Issues for Glucose Testing Devices 5.6 Limitations of Existing Glucose Testing 5.7 Potential Areas of Improvement in Blood Glucose Meter Performance 5.8 Blood Glucose Reagent Test Strips 5.9 Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements 5.10 Continuous Glucose Monitoring Technology 5.11 Summary of Technologies Being Explored for Non-invasive Glucose Monitoring 5.12 A1c Monitoring Technology 5.13 Fructosamine Test 5.14 Related Reagents and Equipment 6. Glucose Testing Devices on the Market 6.1 Hand-Held Blood Glucose Meters and Strips for Self-testing 6.2 Point of Care Blood Glucose Meters for Professional Use 6.3 Clinical Blood Chemistry Analyzers 6.4 Continuous Glucose Patient Monitoring Systems 6.5 Non-Invasive Glucose Patient Monitoring Systems 6.6 A1c Testing 6.7 New Product Launches 6.8 Blood Glucose Meters, CGMs, and Data Management Software in Development 6.9 Recent Industry Activity 6.10 M&A Activity 7. Business Trends in Glucose Testing 7.1 Drivers of Clinical Glucose Testing 7.2 Competition for Professional POC Glucose Testing 7.3 Healthcare Cost Controls 7.4 Changes in Patient Management 7.5 Regionalization of Laboratory Care 7.6 Satellite Facilities 7.7 Professional Point-of-Care Testing 7.8 Factors Affecting OTC Medical Product Distribution 7.9 Drug Stores Critical to the Diabetic Care Category 7.10 Drivers of OTC and Self-Testing Markets 7.11 Cost Elements of Glucose Self-Testing 7.12 Costs of Doing Business in Europe 7.13 Drivers of European Diagnostics Testing 7.14 Cost Containment in Europe 7.15 Blood Glucose Self-Testing Insurance Coverage and Reimbursement 7.15.1 American OTC Testing and Self-Testing Reimbursement 7.15.2 European Reimbursement 7.16 Reimbursement Challenges 7.16.1 New Medicare Part B 7.17 Managed Care 7.18 Government Regulation of Medical Devices 7.18.1 U.S. Regulations 7.18.2 E.U. Regulations 7.18.3 U.K. Regulations 7.19 Clinical Laboratory Improvement Act (CLIA) 7.19.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems 7.20 FDA Labeling Requirements 7.21 Legal Liability for Glucose Meters 7.22 FDA's Artificial Pancreas Guidance Document 8. Technology Trends 8.1 Improving Today's Over-The-Counter (OTC) Blood Glucose Meters 8.2 Biosensor Technology 8.3 Artificial Pancreas 8.4 Telemedicine 8.5 Non-Traditional Methods for Sample Collection 8.6 Data Management Companies Mentioned - A. Menarini Diagnostics - 9.2 Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - All Medicus - AMS Alliance - Apex Biotechnology Corporation - ARKRAY USA - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Diatron - Echo Therapeutics - Entra Health Systems - Fora Care - FIFTY50 Medical, Inc. - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GlySens - Hainice Medical - HemoCue (a Quest Diagnostics company) - Home Diagnostics - Infopia - IN4 Technology - Integrity Applications - International Techidyne Corporation (ITC) - Instrumentation Laboratory Company - i-Sens - Jant Pharmacal - Johnson & Johnson - LabStyle Innovations Corporation - LifeHealth, LLC - Medtronic - Miraculins - Nipro Diagnostics - Nova Biomedical - Polymer Technology Systems - Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.) - Radiometer Medical - Roche Diagnostics - Senseonics - 77 Elektronika Kft. - Siemens AG - Smiths Group - TaiDoc Technology - Techno Medica Co., Ltd. - Telcare - Tokyo Boeki Medisys - US Diagnostics - Ypsomed Holding - YSI Life Sciences For more information visit http://www.researchandmarkets.com/research/m5...od_glucose About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 44.24 (-0.12), MDT: 87.04 (-0.04), JNJ: 119.92 (-0.80)
World Glucose Self-Testing Markets 2016 - Undergoing a Significant Transition Driven by the Advent of New Analytical Technologies
M2 - Wed Jan 13, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/x53b9f/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson - LabStyle Innovations Corporation - Livongo Health - Medtronic - Miraculins - Nipro Corporation For more information visit http://www.researchandmarkets.com/research/x5...ld_glucose
JNJ: 119.92 (-0.80), ABT: 44.24 (-0.12), MDT: 87.04 (-0.04)
GlucoTrack® Maker Hires Chief Operating Officer
PR Newswire - Tue Jan 12, 8:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it has hired Eran Cohen as its Chief Operating Officer (COO).
ALGN: 94.82 (+0.11), LMNS: 13.76 (+0.04)
Global Self-monitoring Blood Glucose Devices Market 2015-2019
M2 - Mon Jan 04, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/qblfrr/global) has announced the addition of the "Global Self-monitoring Blood Glucose Devices Market 2015-2019" report to their offering. The global self-monitoring blood glucose devices market to grow at a CAGR of 10.47% over the period 2014-2019. Global Self-monitoring Blood Glucose Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Self-monitoring blood glucose device is a home-based electronic device. It consists of a glucose sensor and a transmitter that transmits information about glucose levels through radiowaves from the sensor to a receiver, where it is displayed. The regular usage of self-monitoring blood glucose devices can improve self-management of diabetes and prompt an individual to undergo proper diabetes treatment. Though diabetes is a chronic metabolic condition, it can be controlled with proper medication, and dietary and lifestyle management. Most people prefer SMBG devices for convenient monitoring of blood glucose levels. Moreover, regular blood glucose testing is the cornerstone of effective diabetes management. Usage of blood glucose test strips and meters at home can help patients obtain an accurate blood glucose level reading within few seconds. This trend is anticipated to have a significant impact on the SMBG devices market. According to the report, according to WHO, the number of people aged 60 and above will increase tremendously by 2050. By 2030, more than 22% of the world's population will be over 65 years. Almost one-third of the elderly people over the age of 65 are affected by diabetes. The Americas is reported to have a high elderly population, which is estimated to grow at a minimal rate by 2050. Similarly, in Europe, the elderly population will increase by 2050 because of an increase in life expectancy and advances in the healthcare industry. The percentage of the elderly population in APAC is low, including China and India. However, the region will have the largest aging population by 2050. Further, the report states that the presence of alternative methods of glucose monitoring could hinder the growth of the SMBG devices market. Key vendors - Abbott Laboratories - Arkray - Bayer Healthcare - LifeScan - Roche Diagnostics Other prominent vendors - Animas - B. Braun Melsungen - Bionime - Bioptik Technology - Chongqing Haray International Business - Dexcom - Gluco-Ease - LabStyle Innovations - Integrity Applications - M Pharmaceutical - Medtronic - Medisana - Nipro Diagnostics - Nova Biomedical - OrSense - Sunrising Enterprise - Tekcapital - Grove Instruments - Wuhan HNC Technology Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: SMBG: An overview Part 06: Incidence and prevalence Part 07: Market landscape Part 08: Market segmentation by type of SMBG components Part 09: Geographical segmentation Part 10: Market drivers Part 11: Impact of drivers Part 12: Market challenges Part 13: Impact of drivers and challenges Part 14: Market trends Part 15: Vendor landscape Part 16: Key Vendor Analysis Part 17: Appendix For more information visit http://www.researchandmarkets.com/research/qblfrr/global
ABT: 44.24 (-0.12), MDT: 87.04 (-0.04)
GlucoTrack® Hires International Sales and Business Development Manager
PR Newswire - Thu Dec 10, 10:40AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced today that it has hired Boudewijn Baks as International Sales and Business Development Manager for its non-invasive glucose measuring device, GlucoTrack®.
GlucoTrack® Moves Forward with FDA Approval Process
PR Newswire - Thu Oct 29, 10:42AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced today that on October 19, 2015, it met with the U.S. Food and Drug Administration (FDA), to discuss its clinical trial protocol for GlucoTrack® Model DF-F.
GlucoTrack® Maker Holds First International Distributor Conference
PR Newswire - Mon Oct 26, 8:01AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced that it held its first Distributors Conference in Cyprus, Greece from October 12 through October 15, 2015. 13 European distributors were present as well as delegations from China, Hong Kong and Israel.
Non-Invasive Glucose Monitoring Patent Landscape Report 2015-2019
M2 - Mon Sep 28, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4bzc7/noninvasive) has announced the addition of the "Non-Invasive Glucose Monitoring Patent Landscape" report to their offering. The global glucose monitoring device market is estimated to reach $14 billion by 2019. To this date, the conventional technique to measure glucose still involves drawing blood (finger pricking), which can cause pain and discomfort for the patient. Hence, the need to find a non-invasive technique to monitor glucose. Many companies have tried to develop non-invasive technology and device for glucose monitoring, but so far with no success. A few devices had obtained approval from the authorities in the USA or Europe before being abandoned : GlucoWatch (Cygnus), Pendra (Pendragon Medical), NBM-200G (OrSense) or HG1-c (C8 MediSensors). Recently, Integrity Applications received the European CE Mark and launched its GlucoTrack DF-F device late 2014 in Europe. While several minimally-invasive devices are now commercially available, bringing to the market a totally non-invasive device would represent a great change for the market and the diabetics. The renewed IP interest for this topic observed recently shows the desire of players to overcome the same cause of failure faced in the last 3 decades, reliability and accuracy of the technology. The IP and the market for non-invasive monitoring of glucose are driven by the ever increasing diabetic population around the world as well as the recent sizeable democratization of wearable sensors for health monitoring. The spectrum of technologies investigated to monitor glucose non-invasively is very broad. Spectrometry is the most trendy technology. Spectrometry regroups various techniques, but they don't all receive the same focus. The spectrum of sample targets studied to perform a non-invasive measurement is also really broad. The detection of glucose level at the skin level or in the blood vessels are the most investigated. But techniques allowing a detection at the level of the eye are also considered and a new comer in the non-invasive glucose monitoring domain is investing mostly in this approach. Key Features Of The Report: - Time evolution of patent publications and countries of patent filings - Current legal status of patents - Ranking of main patent applicants - Joint developments and IP collaboration network of main patent applicants - Key patents - Granted patents near expiration - Relative strength of main companies IP portfolio - Non-invasive glucose monitoring IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy - The report also provides an extensive Excel database with all patents analyzed in the study Objective Of The Report: - Understand the IP landscape for non-invasive glucose monitoring - Identify key patents - Understand trends in non-invasive glucose monitoring IP - Classify the major players in noninvasive glucose monitoring IP and the relative strength of their patent portfolio - Identify new players in non-invasive glucose monitoring IP - Identify IP collaboration networks between key players Companies Mentioned - Abbott - Animas Technologies - Bayer Healthcare - Cercacor - Futrex - Google - InLight Solutions - Integrity Applications - Key Player Selection - Masimo - OrSense - Panasonic - Roche Diagnostics - Samsung Electronics - Sensys Medical - Toshiba For more information visit http://www.researchandmarkets.com/research/v4...oninvasive
World Glucose Self-Testing Markets Report 2015
M2 - Tue Sep 15, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2qfkx/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Detailed tables and charts with sales forecasts and market share data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - Partial List - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/z2...ld_glucose
JNJ: 119.92 (-0.80), ABT: 44.24 (-0.12)
Integrity Applications Submits Pre-Submission Documents for the GlucoTrack model DF-F to U.S. FDA
PR Newswire - Thu Aug 13, 1:54PM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack® model DF-F noninvasive glucose measurement device, has announced that on August 10th, 2015 it submitted pre-submission documents to the U.S. Food and Drug Administration (the "FDA" in connection with its proposed future application for FDA approval of its U.S. clinical trial protocol.
Integrity Applications, Inc. Announces Adjournment of Annual Meeting
PR Newswire - Wed Jul 22, 3:39PM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack model DF-F noninvasive glucose monitoring device, announced today that its annual meeting of stockholders scheduled for, and convened on July 22, 2015, was adjourned due to the lack of requisite quorum. Only stockholders of record on the record date, June 2, 2015, are entitled to and are being requested to vote.
Faith Comes By Hearing Enlists Expertise of IAI to Reach World's 'unconnected' with Digital Bible
PRWeb - Tue May 12, 9:31AM CDT
After launching their aerospace division at the beginning of this year and establishing their Advisory Council of esteemed space and aeronautical professionals in March, Faith Comes By Hearing continues to press forward with their ambitious agenda to provide digital Bible access to the most remote and hard-to-reach regions on the planet. Continuing this quick pace of progress, FCBH has awarded a contract to Integrity Applications Incorporated (IAI) to determine the best way to provide the Digital Bible to 'unconnected' people in the Middle East & North Africa, Southeast Asia, and China by leveraging space and telecommunications capabilities.
Integrity Applications Signs Distribution Agreements for Its GlucoTrack® Model DF-F Glucose Monitoring Device in Hong-Kong and China
PR Newswire - Tue Feb 17, 8:25AM CST
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into distribution agreements for the GlucoTrack model DF-F device with LifeCaring Technologies Limited (H.K.) and Guangzhou Guang Yuan Biological Pharmaceutical Co. Ltd. in Hong-Kong and in China, respectively. According to the International Diabetes Federation, as of 2013 a total of about 0.5 million people with diabetes, or 9.5 percent of the adult population, in Hong-Kong, and a total of about 98 million people with diabetes, or 9.5 percent of the adult population, in China have diabetes.
Integrity Applications, Inc. Announces Completion of Successful $8.5 Million Equity Financing
PR Newswire - Mon Jan 05, 9:52AM CST
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, announced today that, on December 31, 2014, it raised an aggregate of $1,647,450 through the sale in a private placement transaction of 1,647.45 units (each a "Unit" and, collectively, the "Units" , at a price of $1,000 per Unit. Each Unit consists of: (a) one share of Integrity's Series B 5.5% Convertible Preferred Stock (the "Series B Preferred Stock" , (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock.
GlucoTrack® Maker Submitted Pre-Submission Supplement to US FDA
PR Newswire - Wed Jun 01, 8:06AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes, announced that it has set a conference call with the United States Food and Drug Administration (FDA), expected to take place in July 2016, for further discussion regarding the Company's pre-submission supplement (including clinical trial protocol) for its GlucoTrack® Model DF-F device submitted to the FDA for review on May 10, 2016. Such protocol was modified to reflect FDA remarks and discussions with the Company during a Pre-Submission meeting which took place in October 2015. Following the July discussion and subject to FDA approval of the Company's clinical trial protocol, the Company plans to initiate the pivotal clinical study in the third quarter of 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.90 (+0.23)
GlucoTrack® maker to Present at Marcum and LD Micro Investor Conferences on June 2nd in New York City and June 7th in Los Angeles
PR Newswire - Tue May 31, 8:13AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that CEO Avner Gal will present at the Marcum and LD Micro investor conferences on Thursday, June 2nd at 11:30 am EDT and Tuesday, June 7th at 11:30 am PDT, respectively.
GlucoTrack® Maker Names Two New Board Members
PR Newswire - Wed Mar 23, 8:30AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced today that it appointed Angela Strand and Leslie Seff to its Board of Directors, effective March 23, 2016. Ms. Strand will also chair the newly formed Nominating and Corporate Governance Committee of the Board.
JNJ: 119.92 (-0.80), NKTR: 17.26 (-0.46)
Blood Glucose Testing and Diabetes Management Study 2015
M2 - Tue Feb 02, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5ttq8/blood_glucose) has announced the addition of the "Blood Glucose Testing and Diabetes Management" report to their offering. The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing - or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor - has emerged as a strong force in the blood glucose testing segment. The purpose of this report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Key Topics Covered: 1. Overview 2. Diabetes 2.1 Demographics of Diabetes 2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes 2.3 Economics of Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 3.1 Worldwide Glucose Testing Market 3.2 U.S. Market 3.3 European Market 3.4 Asian Market 3.5 Competitive Situation 3.6 Market Drivers and Restraints 3.7 Market and Product Trends 3.8 Strategic Recommendations 3.9 Competitive Strategies 3.10 New Opportunities in the Professional Blood Glucose Meter Market 3.11 Adjacent Markets 4. Glucose Diagnostic and Monitoring Recommendations 4.1 Diagnosis of Diabetes Mellitus 4.2 Tight Glucose Control in Treating Diabetes 4.3 Recommendations for Glucose Control in Diabetic Patients 4.4 Hypoglycemia and Treatment 5. Glucose Testing Technology Platforms and Consumable Products 5.1 Types of Glucose Determination Technologies 5.2 Enzymatic Reactions Used to Determine Glucose Concentrations 5.3 Development of Blood Glucose Monitors: A Historical Evaluation 5.4 Accuracy and Precision in Glucose Meters 5.5 Key Issues for Glucose Testing Devices 5.6 Limitations of Existing Glucose Testing 5.7 Potential Areas of Improvement in Blood Glucose Meter Performance 5.8 Blood Glucose Reagent Test Strips 5.9 Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements 5.10 Continuous Glucose Monitoring Technology 5.11 Summary of Technologies Being Explored for Non-invasive Glucose Monitoring 5.12 A1c Monitoring Technology 5.13 Fructosamine Test 5.14 Related Reagents and Equipment 6. Glucose Testing Devices on the Market 6.1 Hand-Held Blood Glucose Meters and Strips for Self-testing 6.2 Point of Care Blood Glucose Meters for Professional Use 6.3 Clinical Blood Chemistry Analyzers 6.4 Continuous Glucose Patient Monitoring Systems 6.5 Non-Invasive Glucose Patient Monitoring Systems 6.6 A1c Testing 6.7 New Product Launches 6.8 Blood Glucose Meters, CGMs, and Data Management Software in Development 6.9 Recent Industry Activity 6.10 M&A Activity 7. Business Trends in Glucose Testing 7.1 Drivers of Clinical Glucose Testing 7.2 Competition for Professional POC Glucose Testing 7.3 Healthcare Cost Controls 7.4 Changes in Patient Management 7.5 Regionalization of Laboratory Care 7.6 Satellite Facilities 7.7 Professional Point-of-Care Testing 7.8 Factors Affecting OTC Medical Product Distribution 7.9 Drug Stores Critical to the Diabetic Care Category 7.10 Drivers of OTC and Self-Testing Markets 7.11 Cost Elements of Glucose Self-Testing 7.12 Costs of Doing Business in Europe 7.13 Drivers of European Diagnostics Testing 7.14 Cost Containment in Europe 7.15 Blood Glucose Self-Testing Insurance Coverage and Reimbursement 7.15.1 American OTC Testing and Self-Testing Reimbursement 7.15.2 European Reimbursement 7.16 Reimbursement Challenges 7.16.1 New Medicare Part B 7.17 Managed Care 7.18 Government Regulation of Medical Devices 7.18.1 U.S. Regulations 7.18.2 E.U. Regulations 7.18.3 U.K. Regulations 7.19 Clinical Laboratory Improvement Act (CLIA) 7.19.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems 7.20 FDA Labeling Requirements 7.21 Legal Liability for Glucose Meters 7.22 FDA's Artificial Pancreas Guidance Document 8. Technology Trends 8.1 Improving Today's Over-The-Counter (OTC) Blood Glucose Meters 8.2 Biosensor Technology 8.3 Artificial Pancreas 8.4 Telemedicine 8.5 Non-Traditional Methods for Sample Collection 8.6 Data Management Companies Mentioned - A. Menarini Diagnostics - 9.2 Abaxis, Inc. - Abbott Laboratories - ACON Laboratories - AgaMatrix - Alere - All Medicus - AMS Alliance - Apex Biotechnology Corporation - ARKRAY USA - Bayer - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Diatron - Echo Therapeutics - Entra Health Systems - Fora Care - FIFTY50 Medical, Inc. - Genesis Health Technologies - GenExel-Sein - GlucoPlus - GlySens - Hainice Medical - HemoCue (a Quest Diagnostics company) - Home Diagnostics - Infopia - IN4 Technology - Integrity Applications - International Techidyne Corporation (ITC) - Instrumentation Laboratory Company - i-Sens - Jant Pharmacal - Johnson & Johnson - LabStyle Innovations Corporation - LifeHealth, LLC - Medtronic - Miraculins - Nipro Diagnostics - Nova Biomedical - Polymer Technology Systems - Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.) - Radiometer Medical - Roche Diagnostics - Senseonics - 77 Elektronika Kft. - Siemens AG - Smiths Group - TaiDoc Technology - Techno Medica Co., Ltd. - Telcare - Tokyo Boeki Medisys - US Diagnostics - Ypsomed Holding - YSI Life Sciences For more information visit http://www.researchandmarkets.com/research/m5...od_glucose About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 44.24 (-0.12), MDT: 87.04 (-0.04), JNJ: 119.92 (-0.80)
World Glucose Self-Testing Markets 2016 - Undergoing a Significant Transition Driven by the Advent of New Analytical Technologies
M2 - Wed Jan 13, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/x53b9f/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson - LabStyle Innovations Corporation - Livongo Health - Medtronic - Miraculins - Nipro Corporation For more information visit http://www.researchandmarkets.com/research/x5...ld_glucose
JNJ: 119.92 (-0.80), ABT: 44.24 (-0.12), MDT: 87.04 (-0.04)
GlucoTrack® Maker Hires Chief Operating Officer
PR Newswire - Tue Jan 12, 8:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it has hired Eran Cohen as its Chief Operating Officer (COO).
ALGN: 94.82 (+0.11), LMNS: 13.76 (+0.04)
Global Self-monitoring Blood Glucose Devices Market 2015-2019
M2 - Mon Jan 04, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/qblfrr/global) has announced the addition of the "Global Self-monitoring Blood Glucose Devices Market 2015-2019" report to their offering. The global self-monitoring blood glucose devices market to grow at a CAGR of 10.47% over the period 2014-2019. Global Self-monitoring Blood Glucose Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Self-monitoring blood glucose device is a home-based electronic device. It consists of a glucose sensor and a transmitter that transmits information about glucose levels through radiowaves from the sensor to a receiver, where it is displayed. The regular usage of self-monitoring blood glucose devices can improve self-management of diabetes and prompt an individual to undergo proper diabetes treatment. Though diabetes is a chronic metabolic condition, it can be controlled with proper medication, and dietary and lifestyle management. Most people prefer SMBG devices for convenient monitoring of blood glucose levels. Moreover, regular blood glucose testing is the cornerstone of effective diabetes management. Usage of blood glucose test strips and meters at home can help patients obtain an accurate blood glucose level reading within few seconds. This trend is anticipated to have a significant impact on the SMBG devices market. According to the report, according to WHO, the number of people aged 60 and above will increase tremendously by 2050. By 2030, more than 22% of the world's population will be over 65 years. Almost one-third of the elderly people over the age of 65 are affected by diabetes. The Americas is reported to have a high elderly population, which is estimated to grow at a minimal rate by 2050. Similarly, in Europe, the elderly population will increase by 2050 because of an increase in life expectancy and advances in the healthcare industry. The percentage of the elderly population in APAC is low, including China and India. However, the region will have the largest aging population by 2050. Further, the report states that the presence of alternative methods of glucose monitoring could hinder the growth of the SMBG devices market. Key vendors - Abbott Laboratories - Arkray - Bayer Healthcare - LifeScan - Roche Diagnostics Other prominent vendors - Animas - B. Braun Melsungen - Bionime - Bioptik Technology - Chongqing Haray International Business - Dexcom - Gluco-Ease - LabStyle Innovations - Integrity Applications - M Pharmaceutical - Medtronic - Medisana - Nipro Diagnostics - Nova Biomedical - OrSense - Sunrising Enterprise - Tekcapital - Grove Instruments - Wuhan HNC Technology Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: SMBG: An overview Part 06: Incidence and prevalence Part 07: Market landscape Part 08: Market segmentation by type of SMBG components Part 09: Geographical segmentation Part 10: Market drivers Part 11: Impact of drivers Part 12: Market challenges Part 13: Impact of drivers and challenges Part 14: Market trends Part 15: Vendor landscape Part 16: Key Vendor Analysis Part 17: Appendix For more information visit http://www.researchandmarkets.com/research/qblfrr/global
ABT: 44.24 (-0.12), MDT: 87.04 (-0.04)
GlucoTrack® Hires International Sales and Business Development Manager
PR Newswire - Thu Dec 10, 10:40AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced today that it has hired Boudewijn Baks as International Sales and Business Development Manager for its non-invasive glucose measuring device, GlucoTrack®.
GlucoTrack® Moves Forward with FDA Approval Process
PR Newswire - Thu Oct 29, 10:42AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced today that on October 19, 2015, it met with the U.S. Food and Drug Administration (FDA), to discuss its clinical trial protocol for GlucoTrack® Model DF-F.
GlucoTrack® Maker Holds First International Distributor Conference
PR Newswire - Mon Oct 26, 8:01AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes, announced that it held its first Distributors Conference in Cyprus, Greece from October 12 through October 15, 2015. 13 European distributors were present as well as delegations from China, Hong Kong and Israel.
Non-Invasive Glucose Monitoring Patent Landscape Report 2015-2019
M2 - Mon Sep 28, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4bzc7/noninvasive) has announced the addition of the "Non-Invasive Glucose Monitoring Patent Landscape" report to their offering. The global glucose monitoring device market is estimated to reach $14 billion by 2019. To this date, the conventional technique to measure glucose still involves drawing blood (finger pricking), which can cause pain and discomfort for the patient. Hence, the need to find a non-invasive technique to monitor glucose. Many companies have tried to develop non-invasive technology and device for glucose monitoring, but so far with no success. A few devices had obtained approval from the authorities in the USA or Europe before being abandoned : GlucoWatch (Cygnus), Pendra (Pendragon Medical), NBM-200G (OrSense) or HG1-c (C8 MediSensors). Recently, Integrity Applications received the European CE Mark and launched its GlucoTrack DF-F device late 2014 in Europe. While several minimally-invasive devices are now commercially available, bringing to the market a totally non-invasive device would represent a great change for the market and the diabetics. The renewed IP interest for this topic observed recently shows the desire of players to overcome the same cause of failure faced in the last 3 decades, reliability and accuracy of the technology. The IP and the market for non-invasive monitoring of glucose are driven by the ever increasing diabetic population around the world as well as the recent sizeable democratization of wearable sensors for health monitoring. The spectrum of technologies investigated to monitor glucose non-invasively is very broad. Spectrometry is the most trendy technology. Spectrometry regroups various techniques, but they don't all receive the same focus. The spectrum of sample targets studied to perform a non-invasive measurement is also really broad. The detection of glucose level at the skin level or in the blood vessels are the most investigated. But techniques allowing a detection at the level of the eye are also considered and a new comer in the non-invasive glucose monitoring domain is investing mostly in this approach. Key Features Of The Report: - Time evolution of patent publications and countries of patent filings - Current legal status of patents - Ranking of main patent applicants - Joint developments and IP collaboration network of main patent applicants - Key patents - Granted patents near expiration - Relative strength of main companies IP portfolio - Non-invasive glucose monitoring IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy - The report also provides an extensive Excel database with all patents analyzed in the study Objective Of The Report: - Understand the IP landscape for non-invasive glucose monitoring - Identify key patents - Understand trends in non-invasive glucose monitoring IP - Classify the major players in noninvasive glucose monitoring IP and the relative strength of their patent portfolio - Identify new players in non-invasive glucose monitoring IP - Identify IP collaboration networks between key players Companies Mentioned - Abbott - Animas Technologies - Bayer Healthcare - Cercacor - Futrex - Google - InLight Solutions - Integrity Applications - Key Player Selection - Masimo - OrSense - Panasonic - Roche Diagnostics - Samsung Electronics - Sensys Medical - Toshiba For more information visit http://www.researchandmarkets.com/research/v4...oninvasive
World Glucose Self-Testing Markets Report 2015
M2 - Tue Sep 15, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2qfkx/world_glucose) has announced the addition of the "World Glucose Self-Testing Markets" report to their offering. The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Detailed tables and charts with sales forecasts and market share data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Self-Testing Technology Platforms and Consumable Products 6. Glucose Self-Testing Meters on the Market: Description of Test Meters 7. Business Trends in the Industry 8. Technology Trends 9. OTC Testing: Critical Issues 10. Current Issues for OTC and Diagnostic Self-Testing 11. SWOT Analysis 12. Company Profiles Companies Mentioned - Partial List - 77 Elektronika Kft. - A. Menarini Diagnostics - ACON Laboratories - ARKRAY USA, Inc. - Abbott Laboratories - AgaMatrix - Allmedicus Co., Ltd. - Apex Biotechnology Corporation - B. Braun Melsungen - Bayer - Bionime - Cambridge Sensors - Cardiocom - DexCom - Diagnostic Devices/Prodigy Diabetes Care - Echo Therapeutics, Inc. - Entra Health Systems - FIFTY50 Medical, Inc. - Fora Care - Genesis Health Technologies - GlucoPlus - GlySens, Inc. - Google - Hainice Medical - Home Diagnostics - IN4 Technology - Infopia - Integrity Applications - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/z2...ld_glucose
JNJ: 119.92 (-0.80), ABT: 44.24 (-0.12)
Integrity Applications Submits Pre-Submission Documents for the GlucoTrack model DF-F to U.S. FDA
PR Newswire - Thu Aug 13, 1:54PM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack® model DF-F noninvasive glucose measurement device, has announced that on August 10th, 2015 it submitted pre-submission documents to the U.S. Food and Drug Administration (the "FDA" in connection with its proposed future application for FDA approval of its U.S. clinical trial protocol. Integrity Applications, Inc. Announces Adjournment of Annual Meeting
PR Newswire - Wed Jul 22, 3:39PM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack model DF-F noninvasive glucose monitoring device, announced today that its annual meeting of stockholders scheduled for, and convened on July 22, 2015, was adjourned due to the lack of requisite quorum. Only stockholders of record on the record date, June 2, 2015, are entitled to and are being requested to vote. Faith Comes By Hearing Enlists Expertise of IAI to Reach World's 'unconnected' with Digital Bible
PRWeb - Tue May 12, 9:31AM CDT
After launching their aerospace division at the beginning of this year and establishing their Advisory Council of esteemed space and aeronautical professionals in March, Faith Comes By Hearing continues to press forward with their ambitious agenda to provide digital Bible access to the most remote and hard-to-reach regions on the planet. Continuing this quick pace of progress, FCBH has awarded a contract to Integrity Applications Incorporated (IAI) to determine the best way to provide the Digital Bible to 'unconnected' people in the Middle East & North Africa, Southeast Asia, and China by leveraging space and telecommunications capabilities.
Integrity Applications Signs Distribution Agreements for Its GlucoTrack® Model DF-F Glucose Monitoring Device in Hong-Kong and China
PR Newswire - Tue Feb 17, 8:25AM CST
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into distribution agreements for the GlucoTrack model DF-F device with LifeCaring Technologies Limited (H.K.) and Guangzhou Guang Yuan Biological Pharmaceutical Co. Ltd. in Hong-Kong and in China, respectively. According to the International Diabetes Federation, as of 2013 a total of about 0.5 million people with diabetes, or 9.5 percent of the adult population, in Hong-Kong, and a total of about 98 million people with diabetes, or 9.5 percent of the adult population, in China have diabetes. Integrity Applications, Inc. Announces Completion of Successful $8.5 Million Equity Financing
PR Newswire - Mon Jan 05, 9:52AM CST
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, announced today that, on December 31, 2014, it raised an aggregate of $1,647,450 through the sale in a private placement transaction of 1,647.45 units (each a "Unit" and, collectively, the "Units" , at a price of $1,000 per Unit. Each Unit consists of: (a) one share of Integrity's Series B 5.5% Convertible Preferred Stock (the "Series B Preferred Stock" , (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock. 
